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Protocol for the perfusion and angiography imaging sub-study of the Third
International Stroke Trial (IST-3) of alteplase treatment within six-hours of
acute ischemic stroke
Joanna M. Wardlaw1,3*, Rudiger von Kummer2, Trevor Carpenter3, Mark Parsons4,
Richard I. Lindley5, Geoff Cohen1, Veronica Murray6, Adam Kobayashi7, Andre Peeters8,
Francesca Chappell3, and Peter A. G. Sandercock1
Rationale Intravenous thrombolysis with recombinant tissue
Plasminogen Activator improves outcomes in patients treated
early after stroke but at the risk of causing intracranial hem-
orrhage. Restricting recombinant tissue Plasminogen Activator
use to patients with evidence of still salvageable tissue, or
with definite arterial occlusion, might help reduce risk,
increase benefit and identify patients for treatment at late
time windows.
Aims To determine if perfusion or angiographic imaging with
computed tomography or magnetic resonance help identify
patients who are more likely to benefit from recombinant
tissue Plasminogen Activator in the context of a large multi-
center randomized trial of recombinant tissue Plasminogen
Activator given within six-hours of onset of acute ischemic
stroke, the Third International Stroke Trial.
Design Third International Stroke Trial is a prospective multi-
center randomized controlled trial testing recombinant tissue
Plasminogen Activator (0·9 mg/kg, maximum dose 90 mg)
started up to six-hours after onset of acute ischemic stroke, in
patients with no clear indication for or contraindication to
recombinant tissue Plasminogen Activator. Brain imaging
(computed tomography or magnetic resonance) was manda-
tory pre-randomization to exclude hemorrhage. Scans were
read centrally, blinded to treatment and clinical information. In
centers where perfusion and/or angiography imaging were
used routinely in stroke, these images were also collected
centrally, processed and assessed using validated visual scores
and computational measures.
Study outcomes The primary outcome in Third International
Stroke Trial is alive and independent (Oxford Handicap Score
0–2) at 6 months; secondary outcomes are symptomatic
and fatal intracranial hemorrhage, early and late death. The
perfusion and angiography study additionally will examine
interactions between recombinant tissue Plasminogen
Activator and clinical outcomes, infarct growth and recanali-
zation in the presence or absence of perfusion lesions and/or
arterial occlusion at presentation. The study is registered
ISRCTN25765518.
Key words: acute stroke therapy, CT scan, ischemic stroke, MRI,
reperfusion, rt-PA
Background
Thrombolysis with recombinant tissue Plasminogen Activator
(rt-PA) improves functional outcome after acute ischemic stroke
(1,2). However, practical questions remain concerning how to
reduce the major hazard (intracranial hemorrhage) and how to
identify determinants of the latest time after stroke when throm-
bolysis might still be effective. Focusing treatment on patients
with still viable tissue or persistent arterial occlusion might help
reduce the risk of intracranial hemorrhage and death with throm-
bolysis, particularly at later time windows (2,3).
The most common scanning used to select patients in trials of
iv rt-PA to date was plain brain computed tomography (CT).
Brain CT scan rapidly and reliably excludes acute intracranial
hemorrhage, stroke mimics and in many ischemic stroke patients,
especially those with moderate to severe stroke symptoms, may
show early ischemic changes (4–8). Early ischemic tissue changes
indicating irreversible injury are subtle, however, during the first
few hours after stroke onset (9), and plain CT does not identify
the full extent of any ‘tissue at risk’ of infarction. Many patients
who might benefit from thrombolysis remain untreated. Reasons
for this are complex and include clinicians’ lack of confidence in
diagnosing hyperacute stroke based on plain CT where the signs
of early ischemia or infarction though frequent (9) are subtle
(10). Magnetic resonance (MR) with diffusion weighted imaging
(DWI) shows acute ischemia very clearly, is very sensitive to acute
ischemic change e.g., cytotoxic edema, although there are very
few direct comparisons of MR with CT in hyperacute stroke (11).
However, MR is not widely available as an emergency investiga-
tion for stroke (12,13) and is not well tolerated by hyperacute
stroke patients (14,15). CT is therefore more practical for use in
patients with acute stroke.
Perfusion imaging
Distinguishing the lesion ‘core’ (i.e., infarction), ‘at risk’ and ‘not
at risk’ tissue has become theoretically possible with CT perfusion
(CTP) or MR DWI and perfusion imaging (MRP). CTP technol-
ogy is now available on most modern CT scanners. Whilst some
advocate widespread use of perfusion imaging (16), and some
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observational studies provide encouraging results (17), several
factors need to be resolved before MRP can be adopted into
clinical practice with confidence.
First, several recent randomized trials of thrombolytic agents
that used MR DWI/MRP mismatch to select patients for inclusion
(18,19), or collected DWI/MRP information at randomization
but randomized on the basis of plain CT brain scanning (20) were
inconclusive or conflicting (DIAS 2, http://www.strokecentre.org/
trials/). Indirect comparisons between RCTs that used plain CT
and MR DWI/MRP showed no clear improvement in functional
outcome or in scoring symptomatic intracranial hemorrhage
(SICH) risk according to MR DWI/MRP tissue status (21,22).
Image processing methods may help to demonstrate alterations in
ischemic tissue growth into the penumbra with successful throm-
bolytic treatment (23), except that some studies that included
patients without MR DWI/MRP mismatch found that about
half the patients without mismatch also had some infarct growth
(so might have benefited from treatment) (24,25). Similarly, some
observational data suggest that CTP did not differentiate core
from salvageable tissue (26).
Second, while MRP or CTP might help visualize the ischemic
tissue, there are as yet unquantified practical drawbacks to MRP,
such that the balance of benefit and harm is unclear. These include:
additional radiation dose with CTP (typically 6 mSv at 80kVp,
100mAs, 8 cm coverage, or about three-years worth of background
radiation); contraindications to intravenous contrast agent in
patients with renal impairment (Nephrogenic Systemic Fibrosis,
NSF,with MRP; lactic acidosis with CTP contrast agents in patients
on oral hypoglycemic agents); contrast reactions (MRP allergies
occur in 1:30 000; CTP allergies occur in 1:10 000); general risks of
MR in stroke patients (e.g. hypoxia with poor airway protection)
(15) and general contraindications to MR (pacemaker); patient
compliance (14,15); (potentially) delayed thrombus lysis (27–30);
and increase in delays to treatment of 10–20 min or longer due
to the additional time required for acquisition and analysis. The
true impact of these practical factors is unclear.
Thirdly, and perhaps the most important factor is the lack of
consensus on how perfusion data should be acquired (31), pro-
cessed (32–34), or interpreted (31). The thresholds that distin-
guish ‘tissue at risk’ from ‘core’ or ‘not at risk’ tissue (31,35), and
definitions of these tissue states (31) are highly variable. A sys-
tematic review of CTP and MRP studies published up to 2011
identified 18 different definitions of tissue at risk and 11 different
definitions of ischemic lesion core (31). Most of these studies were
observational, in which rt-PA was given to various proportions
of patients not by random allocation, or combined data from
randomized patients not selected with mismatch and nonran-
domized patients all with mismatch (36). Further studies pub-
lished since then have added further to the list of parameters and
thresholds (Table 1).
A distillation of current literature identifies most consistently
the following parameters and thresholds (31). However, note that
differences in definitions of unsalvageable tissue (e.g. use of DWI
to indicate lesion ‘core’) (38) (39); and in whether or not reper-
fusion was accounted for (40), contribute to variation in the
quoted values:
• non-salvageable tissue (infarct core):
 CTP, absolute CBV <2 ml/100 g (40);
 MRP, relative CBF <31% (38) or relative CBF 45% (39,41)).
• ‘at risk’, potentially salvageable tissue (penumbra):
 CTP, relative MTT >145% (40) or relative MTT>125% (41);
 MRP, Tmax >6 sec (42–48),
Most of these thresholds were derived using receiver–operator
characteristic curve (ROC) analysis. ROC analyses of perfusion
values in individual voxels are increasingly used to identify
threshold values that differentiate infarction, penumbra and not
at risk tissue, and to test the predictive value of perfusion param-
eters. However, this approach relies on some assumptions that are
not valid in this situation and may lead to spuriously positive
results. Many have not been validated in independent studies so
may overestimate sensitivity and specificity. The literature consis-
tently argues against automated methods of threshold detection
unless there is no alternative (49) as automated ROC curve analy-
sis does not avoid the danger of missing the best threshold, but
increases the danger of producing a biased threshold, the diag-
nostic equivalent of trusting post hoc analyses. ROC curve theory
assumes that (1) there are two distinct groups (diseased and non-
diseased) that can be identified as such by a gold standard, and (2)
each unit-of-analysis in the sample is independent of each other.
There is no problem with (2) if the unit-of-analysis is patients,
and no problem with (1) if the patients may or may not have the
disease in question. However, if the automated ROC curve analy-
ses are being applied to voxels rather than patients, then there are
not two distinct groups of patients, but two distinct types of brain
tissue, i.e., lesion and nonlesion. Voxels from the same brain are
not independent, which violates the second assumption and
would mean that the precision of the estimates could be greatly
inflated. While it is hard to say precisely how the estimates of
threshold, sensitivity and specificity would be affected, one
cannot assume that they would not be. These problems are avoided
by restricting the analyses to validation and comparison of exist-
ing thresholds.
Fourth, how the perfusion information is visualized. Creating
perfusion parameter maps at these thresholds requires image pro-
cessing that is not always available on scanner consoles. Regardless
of whether a threshold-delineated lesion is sought or possible
to obtain, it is often not clear what assumptions underpin the
perfusion processing algorithms or how they relate to the same
Table 1 Proposed perfusion parameters to test
MR perfusion(5) CT perfusion
Raw data Raw data
rCBF rCBF
rCBV rCBV
rMTT (first moment) rMTT (1·45) (12)
TTP (various thresholds) TTP (1·4 wrt normal side)
Tmax plus 2, 4 and 6 s
as per EPITHET (20)
Tmax plus 2, 4 and 6 s as per
EPITHET (20)
ATF ATF
CBFq CBFq (including 12·7 ml/100 g/min) (37)
CBVq CBVq (including < 2·2 ml/100 g)(37)
MTTq MTTq
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parameter produced by another manufacturer (50). The alterna-
tive, offline processing, requires rapid data transfer to a processing
computer. Several pipelines are now available (e.g., Rapid process-
ing of Perfusion and Diffusion (RAPID) (46)) but many scanners
are not linked to the internet, nor do many healthcare providers
have funds for additional processing workstations. A simple visual
assessment of the perfusion defect might provide a valid alterna-
tive, is universally available, requires only minimum parameter
processing on the scanner console, but there are few formal evalu-
ations of visual versus computational processing of perfusion
data or their observer reliability (51–53).
Angiographic and structural imaging markers of
arterial occlusion
The other information that might guide use of thrombolysis,
derivable from CT or MR imaging, is the presence and location of
an occluded artery as this determines the likely extent of the tissue
affected by the stroke (54). An occluded artery may be suspected
by the presence of a hyperattenuated artery on plain CT or an
absent flow void or a hypointense artery on T2/fluid attenuated
inversion recovery (FLAIR) or T2* MR respectively. Disappear-
ance of the hyperattenuated artery/absent flow void (i.e., pre-
sumed recanalization) is associated with improved clinical
outcome with or without rt-PA (55,56) and its persistence is
associated with worse clinical outcome (57). Arterial occlusion
may be identified with computerised axial tomographic angiog-
raphy (CTA) or magnetic resonance angiography (MRA) with
intravenous injection of contrast agent. The angiographic images
are generally faster to acquire than MRP, require some image
reconstruction and careful interrogation, but there is, in general,
less scope for variation in acquisition, processing or interpretation
than with MRP, and the acquisition and image processing are
faster than for MRP. However, there have been many fewer pub-
lications on angiographic imaging and the relationship to likely
rt-PA response and clinical outcomes than for MRP. As with MRP,
several factors need to be addressed before CT or MR angiogra-
phy can used reliably to inform clinical practice.
First, there are no completed randomized trials of rt-PA where
randomization was on the basis of presence or absence of arterial
occlusion, therefore information on the marginal benefit or
hazard of rt-PA in the presence or absence of a visible arterial
occlusion is unknown. Ongoing trials include only patients with
angiography-confirmed arterial occlusion (e.g., DIAS 3 and 4,
http://clinicaltrials.gov/ct2/show/NCT00856661; SYNTHESIS 2
(58); IMS 3, http://clinicaltrials.gov/show/NCT00359424). Some
previous trials tested intra-arterial thrombolysis, but only in
patients with an intra-arterial angiography-proven arterial occlu-
sion (59). It is clear that improved outcome after ischemic stroke
is associated with arterial recanalization in observational studies
with and without thrombolytic treatment (60). Some consider
that rt-PA may only be effective when a visible thrombus is
present. Others consider that the absence of a visible occlusion
may simply reflect lack of sensitivity of imaging to small periph-
eral thrombi or to occlusion at the origin of a proximal major
branch point making that branch ‘invisible’ angiographically, that
in any case the major arteries may be patent when the tissue
arterioles/capillaries are not, and that patients without a visible
arterial occlusion should not be denied thrombolytic treatment
in the absence of further information from RCTs.
Second, the hyperattenuated artery sign is fairly specific and
sensitive for arterial occlusion compared with angiographic
imaging (61–63) especially if thin section slices are used (64).
However more information on the overall sensitivity and speci-
ficity of the hyperattenuated artery/absent flow void for angio-
graphic occlusion in hyperacute stroke would be valuable.
Third, the thrombus attenuation/signal change probably
reflects thrombus composition, but the reliability of the imag-
ing appearance–composition relationship is unknown. Some
thrombi may be relatively isoattenuated with blood probably
due to their relative proportions of red cells, fibrin, cholesterol,
calcium and other constituents. Indeed, there is an emerging
(although conflicting) literature on thrombus attenuation, prob-
able composition and likelihood of rt-PA responsiveness (65–69)
that requires further testing prior to clinical use.
Fourth, angiography can be assessed visually using rating
scores that quantify the degree and extent of arterial occlusion
(Table 2). However, the visual rating scores have problems. They
were originally derived in trials of thrombolysis in myocardial
infarction [e.g., the Thrombolysis in Myocardial Infarction
(TIMI) score] (70) using intra-arterial angiography (IAA) prior
to the availability of CT or MR MRP; many of these scores
combine assessment of the point of arterial occlusion with
adequacy of perfusion of the distal tissue because, at the time, IAA
was the only available tool for assessing tissue perfusion; they are
also used to assess recanalization. Thus, three different compo-
nents of tissue blood supply are rolled into one score. This is
confusing, as to what primarily is being scored (76) e.g., the
parent artery could be open, but the tissue not perfused or the
parent artery which was occluded could reopen but the tissue not
re-perfuse. One score for initial occlusion was described by Mori
and colleagues based on IAA of the cerebral circulation but again
became confused with recanalization (71); the TIMI score (70)
was adapted to the cerebral circulation as the Thrombolysis in
Cerebral Infarction (TICI) score and then further modified to
describe degrees of distal arterial patency (54,75); the TICI and
Arterial Occlusive Lesion (AOL) scales were then edited and used
for categorizing degrees of recanalization after therapy and not
the primary occlusion; these scores also muddle arterial patency
with tissue perfusion, a cardinal cause of confusion (76); finally
there are several further variations on the TICI score (Table 2).
The very limited data on observer reliability of angiography
scoring indicate poor agreement: the intra-observer agreement
between nine neuroradiologists reading intra-arterial angiograms
using the TICI score was poor (kappa <0·2) with little evidence of
improvement with training, possibly because of the conflation of
three concepts inherent in the score (54,77).
Finally, other angiographic features that may influence both
tissue viability and rt-PA response and that are detectable angio-
graphically are the burden of occlusive thrombus (78) and the
adequacy of collateral pathways (79). Several scores exist to code
the collateral circulation (73,80) but these in general have under-
gone little independent validation.
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The Third International Stroke Trial
The Third International Stroke Trial (IST-3) aims to evaluate
whether iv rt-PA in a dose of 0·9 mg/kg (maximum 90 mg), when
administered to a wider range of patients with acute ischemic
stroke than were included in the trials to date, within six-hours of
symptom onset, increases the proportion of people alive and inde-
pendent at six-months (http://www.ist3.com) (1,81,82). In addi-
tion, where data could be collected, IST-3 sought to address
whether perfusion or angiography imaging provided additional
useful and reliable information about which patients were more or
less likely to benefit from rt-PA to inform future clinical practice.
Study objectives
IST-3 is a multicenter prospective, randomized trial testing
whether rt-PA is beneficial in a wider range of patients than meet
the current license criteria. The IST-3 Perfusion and Angiography
Study was embedded in the IST-3 main trial and aimed to provide
substantially more data on patients with and without perfusion
deficits or arterial occlusion, randomized to rt-PA or control, to
determine whether there is a differential benefit in those with,
compared with those without, perfusion lesions or arterial occlu-
sion. It aimed to examine visual assessment versus computational
image processing of perfusion images, and associations between
the amount of ‘tissue at risk’ pre-treatment, clinical features and
outcome. If, as suggested in recent studies, very high proportions
of patients with large artery territory cortical ischemic symptoms
have MR DWI/MRP mismatch within six-hours of stroke (20),
and if rt-PA is effective in those with mismatch, then simply
determining the clinical stroke syndrome and time lapse since
stroke may be almost as effective as complex imaging in guiding
patient selection (as well as being quicker and less expensive).
0 Occluded
Artery completely blocked at 
obstruction point
1 Minimal patency
Some contrast penetrates 
main obstruction point but 
no/minimal opacification of 
artery or branches distally
2 Partial patency
Patency of less than half of 
the lumen at the point of 
obstruction and a) only partly 
filling (<½) or b) incomplete 
filling but ≥½ of the major 
branches of the affected 
artery
a) b)
3 Near normal patency
Patency of more than half of 
the lumen at the point of 
obstruction and filling of most 
of the major branches of the 
affect artery
4 Complete patency
Normal arteries
Fig. 1 Diagram of angiogram appearance according to original TIMI score, modified to focus on the primary point of occlusion and main distal vessels
resulting in final TICI – AOL angiographic score.
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If, on the other hand, the benefits of rt-PA are confined either
to those with imaging evidence of tissue at risk or with arterial
occlusion, regardless of time lapse since onset, and who cannot be
identified by other means, then it will require substantial invest-
ment in imaging services to deliver effective thrombolysis. If
the presence of perfusion-visible tissue at risk has no impact on
responsiveness to rt-PA treatment, then clinicians will have
greater confidence to treat patients on the basis of plain CT (or
MR DWI) and thorough clinical assessment alone, which would
immediately improve access to rt-PA.
Questions
Primary
Is the response to rt-PA treatment, as measured by (1) infarct
growth and (2) functional outcome [modified Rankin Scale
(mRS) 0–2]:
• better in patients with imaging evidence of tissue at risk on
CT/CTP or DWI/MRP than those without tissue at risk?
• better in patients with CT/CTA or MR/MRA proven arterial
occlusion than in patients without such occlusions?
Secondary
• in patients treated with rt-PA versus controls, which perfu-
sion parameter (cerebral blood flow, cerebral blood volume or
mean transit time based), processing method (qualitative,
quantitative) and threshold best predicts (1) infarct growth at
24 hours and (2) good functional outcome at six-months?
• can imaging features on plain CT or MR DWI/FLAIR/T2
reliably differentiate viable from nonviable tissue?
Methods
Patient population
Patients were recruited in IST-3 as per trial protocol (http://
www.ist-3.com) (1,81). To be included in IST-3, patients had to
have: (1) symptoms and signs of clinically definite acute stroke,
(2) known time of stroke onset less than six-hours previously
(patients awaking with stroke were not eligible), (3) either CT or
MR brain scanning had excluded intracranial hemorrhage and
common stroke mimics, and (4) treatment could be started
within six-hours of stroke. The exclusion criteria were: age <18,
and standard contraindications to rt-PA related to high risk of
bleeding. In centers where MR was the brain imaging method,
additional exclusions included standard contraindications to MR
imaging. Patients with symptoms of large and medium-sized cor-
tical, lacunar and posterior circulation stroke were all included,
with no upper age limit. Patients with early visible infarct signs
were also included (though not if established infarct signs were
present as these suggest a stroke onset of more than six-hours
previously). Patients with early infarct signs have a higher risk of
poor outcome compared to patients with no early infarct signs
(4), but in the previous trials, there was no clear evidence of an
interaction between the presence (versus absence) of early infarct
signs and increased risk with rt-PA (9). More versus less extensive
early infarct signs are also associated with worse outcome after
stroke but the interaction with rt-PA is also unclear and will be
tested in IST-3. IST-3 was conducted in hospitals with stroke units
where evidence-based care pathways for stroke (including for
administration of rt-PA) were in use in Europe, Canada and
Australia. Consent procedures were described in the protocol
(http://www.ist-3.com).
Investigational product
IST-3 tested rt-PA (alteplase) total dose 0·9 mg per kg of body
weight up to a maximum of 90 mg versus ‘open control’. Patients
allocated control were to avoid treatment with rt-PA and to
receive stroke care in exactly the same clinical environment as
those allocated ‘immediate rt-PA’.
Clinical outcomes
In IST-3, all patients were followed up at seven-days, hospital
discharge, transfer to another hospital or death, whichever
occurred first, by the Hospital Coordinator at each collaborating
center. Six-months after randomization, patients were followed
up by the central trials office in each country, blind to original
treatment allocation by postal questionnaire or telephone inter-
view or clinic assessment by an independent physician, to record
dependency using the Oxford Handicap Scale (OHS, similar to
the mRS), health-related quality of life and, if dead, then the date
and cause of death.
Primary outcome
The primary outcome measure in IST-3 was the proportion of
patients who were dead or dependent (OHS 3–6) at six-months
after stroke. Symptomatic intracranial hemorrhage, death and
recurrent stroke were also assessed within seven-days, and the
proportion who were dead and alive and independent (OHS 0–2)
at six-months. In IST-3 perfusion and angiography analysis, the
primary outcome measures will be the same clinical measures as
for IST-3; secondary outcomes will include absolute infarct
growth, defined as a change in the extent of hypoattenuated tissue
on CT or of hyperintense tissue on MR FLAIR between baseline
and 24–48 h follow-up, of one point or more on either the IST-3
scale score (83,84) or the Alberta Stroke Program Early CT Score
(ASPECTS) score (85) if in the middle cerebral artery (MCA)
territory.
Perfusion and angiography parameters
and assessment
In centers where perfusion and/or angiography imaging with CT
or MR was performed routinely for acute stroke, data from these
imaging modalities was collected centrally according to estab-
lished IST-3 methods. In those centers, patients were randomized
into IST-3 according to plain CT or MR criteria so that decisions
were not influenced by knowledge of perfusion or angiography
information. As per routine clinical practice, patients with defi-
nite renal impairment (eGFR <30 ml/min/1·73 m2) or on met-
formin were excluded from the perfusion/angiography study.
Reduced eGFR is common on admission to hospital in patients
with acute ischemic stroke and usually normalizes with rehydra-
tion (86) therefore patients with eGFR 30–59 ml/min/1·73 m2
could be included if there was no documented history of renal
impairment and the low eGFR was considered likely to reflect
dehydration, at the discretion of the recruiting physician. Low risk
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MR contrast agents were to be used. Oxygen was continued in MR
or CT where necessary.
Where possible patients were to be examined on the same
scanner at baseline and follow up, although combinations, e.g.,
CT pre-randomization and MR at 24 h follow-up were allowed as
local clinical practice dictated. Basic minimum acquisition stan-
dards were required (Appendix 1). Before a center could partici-
pate in the Perfusion and Angiography Study, a test perfusion
and/or angiogram image data set had to be sent to the IST-3 trial
coordinating center to ensure that the imaging met minimum
standards and that the data could be processed centrally.
The image data were received, linked with their demographic
data and trial records, anonymized and transferred into the image
processing pipeline. Plain CT and MR images were read according
to the IST-3 established structured image analysis protocol
by a panel of experts via a web-based image reading system, the
Systematic Image Review System (SIRS, http://www.neuroimage.
co.uk/).
Structural lesion quantification
All image analysis will be performed blind to treatment allocation
and all clinical baseline and follow-up information. The same
methods will be applied to CT and MR images. These quantify
any signs of acute ischemia as well as the appearance of the under-
lying brain. The structural MR and CT visible lesion are quanti-
fied using the established IST3 coding method. This identifies
firstly whether there is any visible hypoattenuated lesion on CT
and if so the degree (mild – grey matter same as white matter;
severe – grey and white matter lower than white matter) or swell-
ing using a structured scale. The visible lesion on MR is classed as
visible on DWI only, DWI and faint FLAIR/T2, obvious DWI and
FLAIR/T2 or no DWI and only FLAIR/T2. The visible lesion
extent is quantified on structural MR (DWI/FLAIR/T2/GRE) and
plain CT imaging using the IST-3 (10,83) and ASPECTS scores
(85) which, in direct comparisons, have similar inter and intra-
rater reliability (84). The ASPECTS score quantifies both perfu-
sion and structural lesions in the MCA territory (14). The IST-3
score assesses all vascular territories and codes lesion location,
extent, degree of tissue attenuation/signal intensity and mass
effect (83). Acute ischemic lesion swelling is quantified using a
seven-point validated scale (83). The hyperattenuated artery or
absent flow void is scored for presence/absence and location in the
internal carotid artery, MCA mainstem or sylvian branch, ante-
rior cerebral artery, posterior cerebral artery, basilar artery or
combinations thereof (10,55,57). Hemorrhagic transformation is
coded using a system developed for IST-3 that has been used in
several observational studies and that is translatable to methods
for SICH used in other trials (ECASS, ECASS 3 and SITS-MOST)
including the association with neurological deterioration and
imaging findings. The general appearance of the underlying brain
is also scored for prior stroke lesions, leukoaraiosis (87), micro-
bleeds (88) and atrophy (89).
The ‘final infarct’ will also be outlined on the follow-up plain
CT or MR T2 or FLAIR image, blind to all clinical information
and baseline imaging, to provide a ‘final’ lesion for mapping to the
nonsalvageable and at-risk tissue maps.
Perfusion image processing and analysis
We will perform both visual and computational assessment of the
perfusion lesion. Visual scoring will be performed using methods
piloted in a three-center study of perfusion and angiography
imaging within six hours of acute ischemic stroke (the TMRC
Multicenter Acute Stroke Imaging Study, in preparation). All
baseline and follow-up diffusion, perfusion and CT or MR struc-
tural data are registered to the baseline CT volume brain image or
MR DWI B0 image and motion corrected. The primary perfusion
parameter maps are generated centrally using validated in-house
software (32,90), with deconvolution performed using singular
value decomposition (SVD) using a delay insensitive method
(block–circulant matrix) (32,90,91) taking arterial input function
from the proximal contralateral MCA and venous outflow from
the sagittal sinus.
Some studies suggest that although quantitative methods
obtained with deconvolution using an arterial input function
(e.g., Tmax) should confer better quantification of the perfusion
lesion than relative measures of tissue perfusion obtained without
deconvolution (time to peak (TTP)), the latter may be just as
accurate (45), as deconvolution decouples delay in bolus arrival
from tissue perfusion and may negatively impact on prediction of
infarction (48). Other factors that may be unknown at the time of
MRP, such as whether the internal carotid artery is occluded or
tightly stenosed in the neck and will therefore slow bolus arrival
and create the impression of a perfusion lesion unless delay in
bolus arrival is accounted for (92), will be assessed in light of
information from angiographic imaging. For these reasons, we
will test both relative and quantitative perfusion parameters.
We will produce a set of perfusion parameter maps for visual
rating and measurement of lesion volume without any threshold
applied (Table 1): quantitative perfusion with deconvolution
(cerebral blood flow, qCBF; cerebral blood volume, qCBV; mean
transit time, qMTT; time to peak of the residue function, Tmax)
and relative perfusion, i.e., without deconvolution (rCBF; arrival
time fitted, rATF; time to peak, rTTP; peak time fitted, rPTF;
rCmax; full width at half maximum, rFWHM).
Although IST-3 will have collected the largest ever amount of
data on MRP in acute stroke specifically in a randomized trial
of rt-PA to date, we are unlikely to have enough data to derive
thresholds in one half of the data set and then validate these
thresholds in the other half. Therefore, rather than attempting
to derive new thresholds, we will focus on validating existing
published thresholds suggested to be most diagnostic of
nonsalvageable/at risk/not at risk tissue. Therefore, maps of the
following perfusion thresholds will be produced for volumetric
and visual measurement (details in Table 1):
• Representing nonsalvageable tissue:
 on CTP, absolute CBV <2 ml/100 g (40);
 on MRP, relative CBF <31% (38) and relative CBF <40%
(39,41).
• Representing at risk tissue:
 on CTP: rMTT >145% (40);, rMTT>125% (41).
 on MRP: Tmax >6 s (42–48); (Note Tmax >2 s was originally
identified in EPITHET but subsequent analyses and other
groups have identified Tmax >6 s as a preferred threshold).
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The perfusion parameters chosen are designed to reflect com-
monly applied thresholds and image types whilst keeping the total
number of comparisons manageable and restricting the potential
for false positive results. Many of these thresholds have been
defined for one modality only (mostly CTP) but could equally be
applied to MR data and therefore will be tested.
The perfusion lesion extent is quantified visually using the
ASPECTS score (85), subtracting one point from a total of 10
for each MCA ASPECTS region that is in part or wholly affected
by the perfusion lesion even where perfusion image does not
cover the whole ASPECTS region. We will also record if there
was (1) no visible perfusion lesion, (2) a visible perfusion lesion
that was less than 80%, (3) about the same size as, or (4) 20% or
more larger than the structural ischemic lesion by visually-
estimated volume on plain CT or MR DWI/FLAIR, these cut
points chosen to reflect previous studies (17,20). Mismatch
will be defined as a perfusion lesion >20% larger than the struc-
tural lesion. These methods have been evaluated in the TMRC
Multicenter Acute Stroke Imaging Study (in preparation) and
provided reliable associations between baseline imaging and
stroke severity as well as predicting associations with clinical
outcome data.
The perfusion lesion volume will also be measured by manual
outlining by a trained observer blind to clinical and other data on
two of the unthresholded parameter maps from above (qMTT
and rCBF perfusion lesions) to represent at risk tissue and non-
salvageable tissue, respectively. In addition, the perfusion lesion
volume will also be measured on thresholded parameter maps
listed above. These lesions will also be identified using a voxel-
based approach to match geographic association with the “final
infarct” (from the 24-hour follow-up image).
In secondary analyses, we will use the data set to test a range of
alternative thresholds using MiStar analysis software (Parsons,
Bivard, Newcastle, Australia) in a hypothesis generating exercise.
Angiographic image analysis
Using source image data and reconstructed angiographic images
where available, we will assess the location and extent of any
arterial occlusion, its completeness, the presence of collateral
pathways, the clot burden (78) and the attenuation properties
of the occluding thrombus. Location and extent will be coded as
for the hyperattenuated artery/absent flow void in the internal
carotid artery, MCA mainstem or sylvian branch, anterior cere-
bral artery, posterior cerebral artery, basilar artery, vertebral artery
or combinations thereof (10,55,57).
Several scores are available to classify the degree of major
arterial obstruction as discussed earlier (Table 2). Several
combine scoring of the patency of the main affected artery with
the degree of perfusion of that artery’s vascular bed and any
recanalization. Conflating three different concepts, peripheral
microvascular tissue perfusion, primary arterial patency and
recanalization in a single score mixes three separate and pro-
bably semi-independent entities (76). We previously used the
Mori (72) and TIMI (70) scores purely to classify arterial
patency at the primary point of obstruction on CTA and
MRA, and separately used CTP or MRP to classify tissue-level
perfusion and reperfusion which worked well. Other scores
(summarized in Table 2) mixed primary occlusion, perfusion
and recanalization (54,73–75).
In IST-3, we will use a score that combines the best elements
of the TICI (including 2a and 2b) and AOL scores that only
scores angiographic patency at the main point of occlusion
and filling of immediate distal vessels, but not tissue perfusion
or recanalization. This score, used in DIAS 3 and 4 (http://
clinicaltrials.gov/ct2/show/NCT00856661) and IMS-3, (http://
clinicaltrials.gov/show/NCT00359424), is described in Fig. 1.
Recanalization will be indicated by a change in one point
or more on the scale between randomization and follow-up
scans.
We will also code thrombus burden using the Clot Burden
Score (78) as follows: From a total score for normal arteries
of 10, two points are subtracted for thrombus found on MRA
in the supraclinoid ICA and each of the proximal and distal
halves of the MCA trunk. One point is subtracted for thrombus
found in the infraclinoid ICA and A1 segment and for each
affected M2 branch giving a total score for normal arteries
of 10.
We will score Collateral pathways (79) (in patients with ICA/
MCA main stem occlusion only) using the Score for Collateral
Status. Scores are A ‘Good’ (entire MCA distal to the occluded
segment reconstituted with contrast); B ‘Moderate’ (some of the
MCA branches reconstituted within the Sylvian fissure); C ‘Poor’
(only the distal superficial MCA branches reconstituted with
contrast) (80).
The resulting coding forms can be seen at http://www.bric.ed.
ac.uk/research/imageanalysis.html#ais.
Observer reliability
We will test the inter-observer reliability of perfusion lesion
scoring and angiographic image analysis by inviting as many
raters as possible to rate as many of the images as possible via the
SIRS web-based image reading system (http://www.neuroimage.
co.uk/sirs), modified to handle color images and to view two
image modalities from the same acquisition time point (e.g.,
a perfusion and a structural CT image) side by side (SIRS2
sirs2.neuroimage.co.uk/sirs2).
Statistical analysis
The basic questions to be addressed are ‘should perfusion-
structural imaging mismatch’ or ‘arterial occlusion’ influence
whether patients receive rt-PA or not?” We will first compare
imaging variables with each other, then with clinical features and
clinical outcomes and then test for interactions between imaging
variables and rt-PA effects. Thus, we will assess:
• variation in the size of perfusion lesions and proportion
with mismatch for each perfusion parameter tested
• associations between clinical and structural imaging vari-
ables at baseline, perfusion lesion extent and presence/absence
of angiography lesions
• associations between baseline perfusion or angiography
imaging variables and subsequent infarct growth, swelling and
hemorrhagic transformation on follow-up scanning
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• then associations between baseline perfusion and angiogra-
phy lesions and six month functional outcome, and
• then test for an interaction between treatment with rt-PA
and perfusion lesion extent, presence or absence of mismatch,
angiographic arterial occlusion and SICH and six-month
functional outcome.
All analyses will be unadjusted and adjusted for key baseline
variables using an established prognostic model determined in
the IST-3 main trial analysis (93). In most countries, patients are
followed up to 18 months offering the opportunity to examine
long term outcomes.
Second, we will also compare: quantitative perfusion lesion
volume with qualitative visual perfusion lesion assessment as
coded by the ASPECTS score; different perfusion processing algo-
rithms (in this case the in house software and MiStar); and test if
relative (i.e., to the contra-lateral hemisphere) parameters are
more consistent than quantitative parameters between different
software, by comparing (1) the measured volumes of different
perfusion parameter lesions, i.e., mm3, and (2) also by taking
account of geometric concordance.
Power calculation
We estimate that 60% will have mismatch at randomization based
on MTT (17); 70% with mismatch will have infarct growth vs.
30% without mismatch; rt-PA will reduce infarct growth by 20%
in those with, but not those without mismatch (24). At 80%
power and alpha of 0·05, a sample of 100 patients would detect a
27% difference in infarct growth, with versus without rt-PA, in
the presence versus absence of mismatch; 160 patients would
detect a 20% difference in infarct growth; 400 patients would
detect a 15% difference in infarct growth.
Data and safety monitoring
The IST-3 DSMC (details in (82)) met annually to consider trial
recruitment and the unblinded results on safety and efficacy and
recommended that the trial continue to completion. The main
trial results have been published (1).
Study organization and funding
IST-3 is managed by a Steering Committee with indepen-
dent chair. The Perfusion and angiography substudy was
reviewed by the Steering Committee at its annual meetings.
The University of Edinburgh and Lothian Health Board are
joint sponsors for the study acting through the Edinburgh
Clinical Trials Unit and the NHS Lothian R&D Department
and ERI Proposal Administration in a joint office known as
ACCORD (Academic and Clinical Central Office for Research
and Development). IST3 has ethics approval from the UK
MREC (99/0/078), including use of MR instead of CT for base-
line and follow-up imaging and of CT and MR perfusion
and angiography, and for the collection and central analysis
of these data. The perfusion and angiography study was funded
by the Efficacy and Mechanisms Evaluation Programme (EME).
The IST-3 main trial is funded by the UK Medical Research
Council and numerous other bodies in the UK and elsewhere
(details in (1,82)).
Progress and discussion
The baseline characteristics of the 3035 patients recruited in IST-3
at 31 July 2011 when trial recruitment ceased (82), the main trial
results (1) and the IST-3 results in context with all prior rt-PA
trials (2), have been published.
The total patient recruitment in the perfusion and angiogra-
phy study was 473 patients from 48 centers in 8 countries per-
forming CT perfusion and/or angiography and 37 centers in 11
countries performing MR perfusion and/or angiography (Fig. 2).
The 473 total includes 52 patients with only MRP, 321 patients
with only angiography imaging and 100 patients with both per-
fusion and angiography imaging. At randomization, 129 patients
had perfusion and 261 patients had angiography imaging.
At follow-up, 11 patients had perfusion and 117 patients had
angiography imaging. A further 12 patients and 43 patients had
perfusion and angiography imaging respectively at both ran-
domization and follow-up. Therefore, allowing for some patients
having both randomization and follow-up imaging, the total
number of patients with MRP is 141 at randomization and 23 at
follow-up and with angiographic imaging is 304 at randomiza-
tion and 160 at follow-up.
Most imaging at randomization was with CT and at follow-up
was with MR, a consistent pattern throughout the study. Figure 2
details expected against actual recruitment to the perfusion and
angiography study in IST-3. We anticipated recruiting between
four and eight patients per year in up to 15 active centers (i.e.,
between 180 and 360 in total). In the event, we had more centers
that were able to recruit overall, and angiography proved to be
more accessible for acute stroke than MRP, therefore we exceeded
our overall target with 473 patients.
We were concerned that patients randomized in IST-3 with
perfusion or angiography imaging would be different in many
respects to those randomized with a plain CT or MR scan.
However initial analysis of the baseline characteristics indicates
only that patients with perfusion and angiography were
randomized slightly later (median 4·5–6 h versus 3–4·5 h) and
that the randomizing clinician thought that more of the
patients with MRP had a visible ischemic lesion on structural
imaging (but not the patients with angiography). Otherwise,
there was no difference in age, NIHSS, proportion with atrial
fibrillation, predicted outcome, or in the blinded expert reader
interpretation of the plain CT or MR imaging between those
randomized with or without perfusion and/or angiography
imaging. The blinded expert readers did not have access to the
perfusion and angiography imaging, thereby illustrating the
importance of separating the perfusion/angiography images
from the structural image interpretation when trying to deter-
mine the true additional contribution of the perfusion and
angiography.
Publication
All papers will be published in the name of the IST-3 Collabo-
rative Group, Perfusion and Angiography Imaging Study Sub-
group. The raw data and processed data from the IST3 perfusion
project will be made available upon written (email) request to
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researchers or other appropriate individuals. These data will be
published using electronic transfer mechanisms available within
the Division of Clinical Neuroscience, the University of Edin-
burgh or any mechanism provided by the funder, as we did pre-
viously with IST (94), which recently won the 2012 BMC ‘Open
Data’ award (http://www.biomedcentral.com/researchawards/).
These data will not be made available on physical media such as
DVD. The availability of the data will be publicized via the IST3
newsletter/website, University of Edinburgh collections cata-
logue, the SINAPSE collaboration (http://www.sinapse.ac.uk),
the Stroke Imaging Repository (STIR) collaboration and any
mechanisms provided by the funding body. Any such data made
available will be fully, ambiguously and irreversibly rendered
anonymous. All publications resulting from the analysis of
the data collected will also be deposited with the publications
archive.
Funding
IST-3 perfusion and angiography imaging study
The EME is funded by the MRC and NIHR, with contributions
from the CSO in Scotland, NISCHR in Wales and the HSC R&D,
Public Health Agency in Northern Ireland, and is managed by
the NIHR. The views and opinions expressed therein are those of
the authors and do not necessarily reflect those of the funding
agencies or UK Department of Health.
IST-3 main trial funding
Medical Research Council (managed by NIHR on behalf of
the MRC-NIHR partnership), Stroke Association, The Health
Foundation, The Research Council of Norway, AFA Insurances
(Sweden), the Swedish Heart Lung Fund, The Foundation of
Marianne and Marcus Wallenberg, Stockholm County Council
and Karolinska Institute Joint ALF-project grants (Sweden), the
Total IST-3 Patients with perfusion scans
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Fig. 2 Patient accrual in IST-3 perfusion and angiography studies against anticipated targets.
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